<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan E Drutz, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teresa K Duryea, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Diphtheria, tetanus, and pertussis immunization in children and adolescents 7 through 18 years of age will be discussed here. Diphtheria, tetanus, and pertussis immunization in children six weeks through six years of age and other childhood immunizations are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"</a> and  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview"</a>.)</p><p class="headingAnchor" id="H2740352788"><span class="h1">ABBREVIATIONS USED IN THIS TOPIC REVIEW</span><span class="headingEndMark"> — </span>Throughout this topic review, the following abbreviations will be used to refer to diphtheria toxoid-, tetanus toxoid-, and pertussis-containing vaccines for children and adolescents:</p><p class="bulletIndent1"><span class="glyph">●</span>Tdap – Tetanus and reduced diphtheria toxoids, and acellular pertussis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Td – Tetanus toxoid and reduced diphtheria toxoids; also called adult Td, dT, and adult dT</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DTaP – Diphtheria and tetanus toxoids, and acellular pertussis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DTwP – Diphtheria and tetanus toxoids, and whole-cell pertussis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DT – Diphtheria and tetanus toxoids; also called pediatric DT</p><p></p><p class="headingAnchor" id="H4"><span class="h1">VACCINE FORMULATIONS</span><span class="headingEndMark"> — </span>Diphtheria toxoid-, tetanus toxoid-, and/or pertussis-containing vaccines for children age 7 through 18 years include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tdap</strong> – Tdap contains tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. The pertussis antigens that are included vary depending upon the vaccine product  (<a class="graphic graphic_table graphicRef73107" href="/z/d/graphic/73107.html" rel="external">table 1</a>). Two Tdap vaccines are available in the United States [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Boostrix, for use in individuals ≥10 years of age</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adacel, for use in individuals 10 through 64 years of age</p><p></p><p class="bulletIndent2">Tdap must be distinguished from DTaP, which is used in children &lt;7 years. Tdap vaccines contain less diphtheria toxoid and pertussis antigens than DTaP vaccines [<a href="#rid1">1</a>]. Tdap also may contain less tetanus toxoid than DTaP  (<a class="graphic graphic_table graphicRef73107" href="/z/d/graphic/73107.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Vaccine formulations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Td</strong> – Td contains tetanus toxoid and reduced diphtheria toxoid. It is available for individuals ≥7 years.</p><p></p><p class="bulletIndent1">Td must be distinguished from DT, which is used in children &lt;7 years who have contraindications to the pertussis component. Td contains lower doses of diphtheria toxoid and may contain lower doses of tetanus toxoid than DT  (<a class="graphic graphic_table graphicRef73107" href="/z/d/graphic/73107.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monovalent tetanus toxoid </strong>– Monovalent tetanus toxoid (TT) vaccine is no longer available in the United States [<a href="#rid1">1</a>], but may be available in other countries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diphtheria or tetanus toxoid in conjugate vaccines </strong>– Diphtheria toxoid, CRM<sub>197 </sub>(a nontoxic variant of diphtheria toxin), and tetanus toxoid are used as protein conjugates in some childhood vaccines (eg, pneumococcal conjugate vaccine, <em>Haemophilus influenzae</em> type b vaccine, meningococcal conjugate vaccine) to enhance the immune response. When used as protein conjugates, these toxoids do not substitute for diphtheria or tetanus toxoid immunization [<a href="#rid2">2,3</a>]. However, as vaccine components, they may contribute to adverse reactions. (See <a class="local">'Adverse reactions'</a> below and <a class="local">'Contraindications and precautions'</a> below.)</p><p></p><p class="headingAnchor" id="H4050696201"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Routine immunization against diphtheria, tetanus, and pertussis during childhood and adolescence provides protection against these diseases into adulthood, prevents neonatal tetanus, and prevents transmission of pertussis to young infants, who have the greatest risk of mortality. (See  <a class="medical medical_review" href="/z/d/html/8047.html" rel="external">"Clinical manifestations, diagnosis, and treatment of diphtheria"</a> and  <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">"Tetanus"</a> and  <a class="medical medical_review" href="/z/d/html/5995.html" rel="external">"Pertussis infection in infants and children: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Worldwide</strong> – The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fteams%2Fimmunization-vaccines-and-biologicals%2Fdiseases&amp;token=orMeNG1S9%2BGAx7wBzvCzMcig%2BFKBjnete%2FGnpZrGq%2F9zhhHuQUEe2H0bnfh%2Fbg91HU5yyj2L9ghICK%2BU8ZU%2Fnm6BQ%2B9q4Zr2%2F01BK4XSa44%3D&amp;TOPIC_ID=2838" target="_blank">World Health Organization</a> recommends that all children worldwide be immunized against diphtheria, tetanus, and pertussis [<a href="#rid4">4-6</a>]. The recommended schedule includes a booster dose of diphtheria toxoid- and tetanus toxoid-containing vaccine during adolescence. Booster doses of acellular pertussis vaccine during adolescence or maternal pertussis immunization are also suggested for adolescents in countries that have switched from whole-cell to acellular pertussis vaccines for the primary series [<a href="#rid6">6</a>]. (See <a class="local">'Other countries'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States </strong>– Indications for <strong>Tdap</strong> for children ≥7 years and adolescents in the United States include [<a href="#rid1">1,3,7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children age 11 through 12 years (routine immunization)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adolescents age ≥13 years and unimmunized with Tdap (catch-up immunization)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy (a single dose of Tdap is recommended during <strong>each</strong> pregnancy; immunization in pregnancy is discussed separately (see  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unvaccinated or incompletely vaccinated against pertussis and:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Anticipated close contact with an infant &lt;12 months of age (eg, household member, out-of-home caregiver); if possible, Tdap should be given ≥2 weeks before contact with the infant. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At increased risk of pertussis infection (eg, living in or travel to an area with a high rate of endemic pertussis or an outbreak of pertussis; school or workplace outbreak of pertussis; close direct contact with a person with pertussis [eg, family member, residential facility, school-related activity]). (See  <a class="medical medical_review" href="/z/d/html/5997.html" rel="external">"Pertussis infection in infants and children: Treatment and prevention", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>At increased risk of complications from pertussis infection (eg, neurologic, muscular, cardiac, airway, or pulmonary disorder).</p><p></p><p class="bulletIndent2">Complete pertussis vaccination at age 7 years is defined by four or five doses of DTaP at appropriate minimum ages and intervals  (<a class="graphic graphic_table graphicRef117916" href="/z/d/graphic/117916.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Routine immunization'</a>.)</p><p></p><p class="bulletIndent1">Indications for <strong>either Td or Tdap</strong> include [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Wound management  (<a class="graphic graphic_table graphicRef61087" href="/z/d/graphic/61087.html" rel="external">table 3</a>) (see <a class="local">'Wound management'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tetanus or diphtheria disease (see <a class="local">'Natural diphtheria or tetanus infection'</a> below and  <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">"Tetanus", section on 'Active immunization'</a> and  <a class="medical medical_review" href="/z/d/html/8047.html" rel="external">"Clinical manifestations, diagnosis, and treatment of diphtheria", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unimmunized or incompletely immunized close contact of an individual with diphtheria or pertussis disease (see  <a class="medical medical_review" href="/z/d/html/5997.html" rel="external">"Pertussis infection in infants and children: Treatment and prevention", section on 'Prevention'</a> and  <a class="medical medical_review" href="/z/d/html/8047.html" rel="external">"Clinical manifestations, diagnosis, and treatment of diphtheria"</a>)</p><p></p><p class="bulletIndent1">The Advisory Committee on Immunization Practices in the United States provides no preferential recommendation for Td or Tdap, although Tdap is more expensive [<a href="#rid7">7</a>]. </p><p></p><p class="headingAnchor" id="H2651546245"><span class="h1">EFFICACY AND EFFECTIVENESS</span></p><p class="headingAnchor" id="H3096418934"><span class="h2">Protection against disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The efficacy and effectiveness of diphtheria, tetanus, and pertussis immunization vary depending upon the definition used for efficacy (eg, antibody levels correlated with protection or protection from disease) and the number of doses received.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Td</strong> – After a series of three appropriately spaced doses of Td vaccines, approximately 95 percent of adolescents and adults achieve levels of <a class="drug drug_general" data-topicid="8900" href="/z/d/drug information/8900.html" rel="external">diphtheria antitoxin</a> correlated with protection (&gt;0.1 international unit of antitoxin/mL), and virtually all adolescents and adults achieve levels of tetanus antitoxin correlated with protection (&gt;0.1 international unit of antitoxin/mL) [<a href="#rid8">8,9</a>].</p><p></p><p class="bulletIndent2">The estimated efficacy of diphtheria toxoid in the prevention of diphtheria disease is 97 percent [<a href="#rid8">8</a>]. The clinical efficacy of tetanus toxoid has not been studied in vaccine trials [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tdap</strong> – In randomized controlled trials, virtually all adolescent and adult recipients of Tdap developed levels of tetanus and <a class="drug drug_general" data-topicid="8900" href="/z/d/drug information/8900.html" rel="external">diphtheria antitoxin</a> correlated with protection [<a href="#rid1">1,10,11</a>]. Booster response rates to these antigens were achieved in ≥90 percent.</p><p></p><p class="bulletIndent2">In a randomized trial, the efficacy of Tdap in preventing laboratory-confirmed pertussis in adolescents and adults was 92 percent (95% CI 32-99 percent) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Effectiveness</strong> – Vaccine effectiveness is a measure of how well a vaccine works to protect against an infection when the vaccine is used in routine circumstances in the community.</p><p></p><p class="bulletIndent1">The effectiveness of diphtheria, tetanus, and pertussis immunization is demonstrated by the decline of these diseases in the United States after the immunizations were added to the routine immunization schedule in the 1940s  (<a class="graphic graphic_figure graphicRef72244 graphicRef53397 graphicRef62288" href="/z/d/graphic/72244.html" rel="external">figure 1A-C</a>) [<a href="#rid8">8,9,13,14</a>]. Most cases of diphtheria and tetanus in the United States occur in inadequately immunized persons [<a href="#rid8">8,9</a>].</p><p></p><p class="headingAnchor" id="H63148153"><span class="h2">Duration of immunity</span><span class="headingEndMark"> — </span>Levels of diphtheria and tetanus antitoxin diminish with time [<a href="#rid15">15,16</a>]. After completion of routine childhood and adolescent immunization, booster doses of Td are necessary every 10 years. (See <a class="local">'United States'</a> below.)</p><p></p><p class="bulletIndent1">The effectiveness of Tdap in preventing pertussis appears to wane soon after receipt among adolescents who completed childhood vaccination with acellular pertussis vaccines (ie, the cohort born in the late 1990s) rather than a combination of acellular and whole cell vaccines (ie, those born before 1997) [<a href="#rid17">17-23</a>]. The Advisory Committee on Immunization Practices began recommending Tdap for adolescents in 2006 [<a href="#rid24">24</a>]. In pertussis outbreaks during 2005 and 2007, reported effectiveness of acellular pertussis vaccine in preventing laboratory-confirmed or probable pertussis among vaccinated adolescents ranged from 66 to 85 percent [<a href="#rid25">25,26</a>]. In more recent statewide outbreaks, Tdap provided similar modest protection during the first year after vaccination (effectiveness of 64 to 75 percent), but effectiveness quickly waned to approximately 10 percent by ≥4 years [<a href="#rid27">27-29</a>].</p><p></p><p>Despite waning immunity, vaccination continues to be the most effective strategy to reduce pertussis morbidity and mortality [<a href="#rid17">17,30-33</a>]. In another outbreak, children and adolescents who received any doses of acellular pertussis vaccine were less likely to have severe illness or require hospitalization than unvaccinated children, and children and adolescents fully vaccinated with acellular pertussis vaccine had more rapid resolution of coughing [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H2199345843"><span class="h1">SCHEDULE</span></p><p class="headingAnchor" id="H4075526430"><span class="h2">United States</span></p><p class="headingAnchor" id="H4236796058"><span class="h3">Age 7 through 10 years</span><span class="headingEndMark"> — </span>Children 7 through 10 years of age generally do not require immunization with diphtheria toxoid, tetanus toxoid, and pertussis-containing vaccines if they have completed DTaP immunization before age seven years (ie, four or five doses at appropriate minimum ages and intervals)  (<a class="graphic graphic_table graphicRef117916" href="/z/d/graphic/117916.html" rel="external">table 2</a>).</p><p>The catch-up schedule for children age 7 through 10 years of age with incomplete diphtheria, tetanus, and/or pertussis immunization varies with vaccination history.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Previously unvaccinated or unknown vaccination status – </strong>Children 7 through 10 years of age who have never been vaccinated against tetanus, diphtheria, or pertussis or whose vaccination status is unknown should receive a series of three tetanus- and diphtheria-containing vaccines  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">The preferred schedule is a first dose of Tdap (if there are no contraindications to pertussis vaccine  (<a class="graphic graphic_table graphicRef79169" href="/z/d/graphic/79169.html" rel="external">table 5</a>)) to provide protection against pertussis, followed by a second dose of either Td or Tdap ≥4 weeks later and a third dose of either Td or Tdap 6 to 12 months after the second  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>) [<a href="#rid7">7</a>]. (See <a class="local">'Contraindications and precautions'</a> below and <a class="local">'Choice of vaccine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incompletely vaccinated </strong>– Children age 7 through 10 years who are incompletely vaccinated against pertussis and who have no contraindications to pertussis vaccine  (<a class="graphic graphic_table graphicRef79169" href="/z/d/graphic/79169.html" rel="external">table 5</a>) should receive at least one dose of Tdap in their catch-up series, preferably as the first dose, to provide protection against pertussis [<a href="#rid7">7</a>]. Additional doses of either Td or Tdap should be provided as necessary to complete the immunization series  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>). (See <a class="local">'Contraindications and precautions'</a> below and <a class="local">'Choice of vaccine'</a> below.)</p><p></p><p>Children who receive Tdap at age 7 through 9 years as part of a catch-up series should receive another dose of Tdap at age 11 through 12 years [<a href="#rid7">7</a>]. A catch-up Tdap that is administered at age ≥10 years may count as the adolescent Tdap dose. </p><p>The Centers for Disease Control and Prevention has developed a "job aid" to provide guidance for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Ftdap.pdf&amp;token=tOdEoTf5ljtGtizH0uwcXFuJNNpgpl1WuO1vtEtc55yzZoInNMcBIBX4q1qHKaWwvsO%2BP7JR6CHhrs2O5imrXigMpDkmdwHv5aokwullVSQ%3D&amp;TOPIC_ID=2838" target="_blank">catch-up of diphtheria, tetanus, and pertussis immunizations in children age 7 through 18 years of age</a>.</p><p class="headingAnchor" id="H1806807494"><span class="h3">Age 11 through 12 years</span><span class="headingEndMark"> — </span>The adolescent booster dose of Tdap vaccine is routinely recommended at age 11 through 12 years [<a href="#rid1">1</a>]. Thereafter, booster doses of either Td or Tdap vaccine should be given every 10 years [<a href="#rid7">7</a>].</p><p>The adolescent Tdap booster is recommended for children age 11 through 12 years, even if they received Tdap at age 7 through 9 years as part of a catch-up series [<a href="#rid7">7</a>]. The adolescent Tdap booster is also recommended for children who received an inadvertent dose of Tdap or DTaP at age 7 through 9 years. (See <a class="local">'Vaccine mix-up or unnecessary dose'</a> below.)</p><p>Tdap may be given at any interval after the last tetanus toxoid- and diphtheria toxoid-containing vaccine [<a href="#rid7">7</a>]. However, the minimum intervals in the catch-up schedule should continue to be followed  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>).</p><p>The Centers for Disease Control and Prevention has developed a "job aid" to provide guidance for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Ftdap.pdf&amp;token=tOdEoTf5ljtGtizH0uwcXFuJNNpgpl1WuO1vtEtc55yzZoInNMcBIBX4q1qHKaWwvsO%2BP7JR6CHhrs2O5imrXigMpDkmdwHv5aokwullVSQ%3D&amp;TOPIC_ID=2838" target="_blank">catch-up of diphtheria, tetanus, and pertussis immunizations in children age 7 through 18 years of age</a>.</p><p class="headingAnchor" id="H1305122747"><span class="h3">Age 13 and older</span><span class="headingEndMark"> — </span>Adolescents ≥13 years who have not received a dose of Tdap or whose Tdap status is unknown should receive a single dose of Tdap as soon as is feasible. There is no minimum interval between Td and Tdap [<a href="#rid1">1</a>]. If necessary, additional doses of either Td or Tdap should be provided to complete the series  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>) [<a href="#rid7">7</a>].</p><p>Provision of Tdap is particularly important for adolescents who anticipate having close contact with an infant younger than 12 months [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/8044.html" rel="external">"Pertussis infection in adolescents and adults: Treatment and prevention"</a>.)</p><p>The Centers for Disease Control and Prevention has developed a "job aid" to provide guidance for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fdownloads%2Fchild%2Fjob-aids%2Ftdap.pdf&amp;token=tOdEoTf5ljtGtizH0uwcXFuJNNpgpl1WuO1vtEtc55yzZoInNMcBIBX4q1qHKaWwvsO%2BP7JR6CHhrs2O5imrXigMpDkmdwHv5aokwullVSQ%3D&amp;TOPIC_ID=2838" target="_blank">catch-up of diphtheria, tetanus, and pertussis immunizations in children age 7 through 18 years of age</a>.</p><p class="headingAnchor" id="H3333317429"><span class="h2">Other countries</span><span class="headingEndMark"> — </span>Routine immunization schedules vary from country to country. Schedules for individual countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=2838" target="_blank">World Health Organization</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccine-schedule.ecdc.europa.eu%2F&amp;token=hAC5nrgJRAh83rPs4U2YNoCvbRcaKCDdFzcO5xBYnRCBx4Y4AiuicnfZL3B%2BmfLV&amp;TOPIC_ID=2838" target="_blank">European Centre for Disease Prevention and Control</a>.</p><p class="headingAnchor" id="H870954767"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H25"><span class="h2">Contraindications and precautions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> — A contraindication is a condition that increases the risk of a serious adverse reaction [<a href="#rid1">1</a>]. Absolute contraindications to <strong>Tdap and Td</strong> include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component. (See  <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">"Allergic reactions to vaccines"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Referral to an allergist is warranted to evaluate allergy to tetanus toxoid and the possibility of desensitization to tetanus toxoid given the importance of tetanus immunization</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Information about latex in Tdap vaccines is available in the prescribing information, available from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fvaccines-blood-biologics%2Fvaccines%2Fvaccines-licensed-use-united-states&amp;token=wCcUPYLTKXZ5S1UGXUKfKr94oxDQyONzYC1uFsK%2BYnQ2%2B4KaGLMcoHHsAbP1LWfZN0ygLpycExSlzNHyAzL3GOlOTh%2B%2BOgpb44BnyQIFSrI%3D&amp;TOPIC_ID=2838" target="_blank">the US Food and Drug Administration</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For Tdap only,</strong> another absolute contraindication is encephalopathy (eg, coma, decreased level of consciousness, or prolonged seizures) within seven days of the administration of a previous dose of a pertussis-containing vaccine (eg, DTaP, DTwP, Tdap) without another identifiable cause.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Administer Td rather than Tdap (see <a class="local">'Vaccine formulations'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> — Precautions are conditions that may increase the risk for a serious reaction to immunization, cause diagnostic confusion, or compromise the ability of the vaccine to produce immunity [<a href="#rid34">34</a>]. Although immunization generally is deferred in children with precautions, decisions regarding administering diphtheria toxoid, tetanus toxoid, and pertussis-containing vaccines to children and adolescents with precautions should be individualized according the benefits and risks, and reassessed at subsequent immunization visits [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Precautions to immunization with <strong>Td or Tdap</strong> include [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate or severe acute illness with or without fever; immunization should be administered upon recovery</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of Arthus-type reaction after a previous dose of tetanus or diphtheria toxoid-containing vaccines (including <a class="drug drug_pediatric" data-topicid="12931" href="/z/d/drug information/12931.html" rel="external">quadrivalent meningococcal conjugate vaccine</a>) (see <a class="local">'Past cutaneous reactions involving skin necrosis (Arthus-type reaction)'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Guillain-Barré syndrome (GBS) within six weeks after previous dose of tetanus toxoid-containing vaccine (see  <a class="medical medical_review" href="/z/d/html/6235.html" rel="external">"Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis"</a> and <a class="local">'Adverse reactions'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For Tdap only</strong>, another precaution is progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditions that are neither contraindications nor precautions</strong> — The following conditions are <strong>neither</strong> contraindications nor precautions to Tdap vaccine  (<a class="graphic graphic_table graphicRef79169" href="/z/d/graphic/79169.html" rel="external">table 5</a>) [<a href="#rid1">1,34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever ≥105°F (40.5°C) within 48 hours after DTaP or DTwP (not attributable to another cause)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of collapse or shock-like state (ie, hypotonic-hyporesponsive episode) within 48 hours after DTaP or DTwP</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of seizure with or without fever within three days of DTaP or DTwP</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of persistent inconsolable crying lasting &gt;3 hours within 48 hours after receiving DTaP or DTwP</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of extensive limb swelling after DTaP, DTwP, or Td that is not an Arthus-type reaction (see <a class="local">'Past cutaneous reactions involving skin necrosis (Arthus-type reaction)'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Stable or resolved neurologic disorder (eg, well-controlled seizures, developmental delay, cerebral palsy)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of brachial neuritis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Breastfeeding an infant</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunosuppression</p><p></p><p class="headingAnchor" id="H2304969102"><span class="h2">Choice of vaccine</span><span class="headingEndMark"> — </span>The choice of vaccine varies with the age of the child or adolescent and history of Tdap immunization.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tdap preferred</strong> – Tdap 0.5 mL intramuscularly (IM) is preferred to Td [<a href="#rid1">1,7</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the routine adolescent booster dose at age 11 through 12 years of age</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For at least one dose of the catch-up series (ideally the first) in children age 7 through 10 years who are unimmunized or incompletely immunized against diphtheria, tetanus, and/or pertussis  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>) [<a href="#rid7">7</a>] (see <a class="local">'Age 7 through 10 years'</a> above)</p><p></p><p class="bulletIndent2">Although none of the pertussis-containing vaccines are licensed in the United States for children between 7 and 10 years of age, the Advisory Committee on Immunization Practices and American Academy of Pediatrics prefer off-label use of Tdap to DTaP because Tdap causes fewer adverse reactions [<a href="#rid7">7,35,36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For at least one dose (preferably the first) of the catch-up series in a Tdap-naïve child ≥10 years of age (see <a class="local">'Indications'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant women during each pregnancy (see  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Td preferred </strong>– Td 0.5 mL IM is preferred:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children ≥7 years and adolescents who have a contraindication to the pertussis component  (<a class="graphic graphic_table graphicRef79169" href="/z/d/graphic/79169.html" rel="external">table 5</a>) (see <a class="local">'Contraindications and precautions'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No preference between Tdap and Td</strong> – Either Tdap 0.5 mL IM or Td 0.5 mL IM may be administered [<a href="#rid7">7</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the every 10-year tetanus and diphtheria toxoids booster</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For wound management in people who have received at least one dose of Tdap </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For multiple doses in the catch-up immunization schedule for individuals ≥7 years of age</p><p></p><p class="bulletIndent1">Although it is uncertain whether receiving multiple doses of Tdap for the above indications affects pertussis transmission or control, the Advisory Committee on Immunization Practices permits either Tdap or Td for improved flexibility [<a href="#rid7">7</a>]. Both vaccines appear to be safe and immunogenic [<a href="#rid37">37-39</a>]; Tdap is more expensive.</p><p></p><p class="headingAnchor" id="H413979356"><span class="h2">Administration with other vaccines</span><span class="headingEndMark"> — </span>Tdap or Td may be administered at the same visit as other recommended vaccines (eg, meningococcal conjugate vaccine, human papillomavirus, influenza)  (<a class="graphic graphic_figure graphicRef58209" href="/z/d/graphic/58209.html" rel="external">figure 2</a>) [<a href="#rid1">1,40-45</a>].</p><p class="headingAnchor" id="H117306647"><span class="h2">Adverse reactions</span><span class="headingEndMark"> — </span>The safety of Tdap was confirmed in postmarketing surveillance of more than 13,000 adolescents [<a href="#rid46">46</a>]. There was no increased risk of medically attended neurologic, hematologic, or allergic reactions on days 0 to 29 after Tdap vaccination compared with days 30 to 59 after vaccination, nor was there an increased risk of new-onset chronic illness in recipients of Tdap compared with historical recipients of Td. In randomized trials in adult patients, subsequent doses of Tdap also appear to be safe when administered as part of a catch-up series [<a href="#rid47">47</a>] or as the 10-year booster [<a href="#rid37">37,38</a>].</p><p>Adverse reactions to the Tdap vaccine include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local reactions</strong> – Mild local reactions (eg, pain, redness, swelling) may occur after immunization with Td or Tdap. In prelicensure studies, the rates of mild local reactions were similar for Td and Tdap [<a href="#rid48">48</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain – Approximately 70 to 80 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Erythema – Approximately 20 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Swelling – Approximately 20 percent</p><p></p><p class="bulletIndent1">Severe local reactions are less frequent (≤6 percent for either Td or Tdap).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic reactions</strong> – Systemic reactions also may occur after immunization with Td or Tdap [<a href="#rid3">3,48</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever – 3 to 14 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Headache – Approximately 40 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Fatigue – Approximately 30 to 35 percent</p><p></p><p class="bulletIndent1">Fever &gt;102.2°F (39°C), severe headache, and severe fatigue occur in less than 4 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syncope</strong> – Syncope following immunization appears to be more common among adolescents and young adults than other age groups [<a href="#rid1">1,49-51</a>]. Having the recipient sit or lie down for 15 minutes after vaccination may prevent syncopal episodes and secondary injuries. If syncope occurs, patients should be observed until symptoms resolve. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Local and systemic reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Local reactions with skin hemorrhage and necrosis</strong> – Arthus-type reactions can occur after vaccines containing tetanus or diphtheria toxoid [<a href="#rid1">1</a>]. They typically occur 4 to 12 hours after vaccination and are characterized by severe pain, swelling, induration, edema, hemorrhage, and occasionally necrosis at the site of the injection. They generally resolve without sequelae. The history of the reaction should be reviewed to verify the signs and symptoms; consultation with an allergist or immunologist may be warranted. (See <a class="local">'Contraindications and precautions'</a> above and <a class="local">'Past cutaneous reactions involving skin necrosis (Arthus-type reaction)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guillain-Barré syndrome</strong> – There have been rare case reports of GBS following tetanus toxoid-containing vaccines [<a href="#rid1">1,52-54</a>]. However, an association between GBS and tetanus vaccination has not been demonstrated during active surveillance [<a href="#rid1">1,55</a>]. (See  <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis", section on 'Vaccinations'</a>.)</p><p></p><p class="bulletIndent1">GBS also has been reported after meningococcal conjugate vaccine, which may contain diphtheria toxoid as a protein conjugate. The possible association between meningococcal conjugate vaccine and GBS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Adverse events'</a>.)</p><p></p><p class="headingAnchor" id="H1469625928"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H1159191001"><span class="h2">Wound management</span><span class="headingEndMark"> — </span>When tetanus prophylaxis is necessary for wound management  (<a class="graphic graphic_table graphicRef61087" href="/z/d/graphic/61087.html" rel="external">table 3</a>) in children ≥7 years of age, either Tdap or Td may be used [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">"Tetanus"</a> and <a class="local">'Administration with other vaccines'</a> above.)</p><p class="headingAnchor" id="H2885514591"><span class="h2">Past cutaneous reactions involving skin necrosis (Arthus-type reaction)</span><span class="headingEndMark"> — </span>Arthus-type reactions are characterized by painful swelling, erythema, hemorrhage, and sometimes superficial skin necrosis at the site of injection of booster vaccines [<a href="#rid1">1</a>]. They usually begin within a few hours of the injection and peak by 24 hours. The history of the reaction should be reviewed to verify the signs and symptoms; consultation with an allergist or immunologist may be warranted. (See <a class="local">'Adverse reactions'</a> above and  <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">"Drug hypersensitivity: Classification and clinical features", section on 'Arthus reaction'</a>.)</p><p>For patients with a history of Arthus-type reaction after diphtheria or tetanus toxoid-containing vaccine, we agree with the Advisory Committee on Immunization Practices recommendation to defer tetanus toxoid-containing vaccine for a minimum of 10 years after the last dose of tetanus toxoid-containing vaccine [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4287599097"><span class="h2">Incomplete pertussis</span><span class="headingEndMark"> — </span>Adolescents with incomplete pertussis immunization (ie, because there was a precaution to administration of pertussis vaccine during childhood) generally should receive Tdap for their adolescent booster dose [<a href="#rid1">1</a>]. Conditions that were considered precautions to DTaP in the past (but are no longer precautions) are neither contraindications nor precautions for Tdap (eg, history of hypotonic-hyporesponsive episode within 48 hours after DTaP or DTwP; history of persistent, inconsolable crying lasting &gt;3 hours within 48 hours after DTaP or DTwP). (See <a class="local">'Contraindications and precautions'</a> above and  <a class="medical medical_review" href="/z/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Adverse reactions'</a>.)</p><p class="headingAnchor" id="H2896684958"><span class="h2">Incomplete records</span><span class="headingEndMark"> — </span>Serologic testing can be performed in children and adolescents who have an adequate history of immunization against diphtheria and tetanus but incomplete documentation [<a href="#rid1">1</a>]. If tetanus and <a class="drug drug_general" data-topicid="8900" href="/z/d/drug information/8900.html" rel="external">diphtheria antitoxin</a> concentrations are ≥0.1 international units/mL, previous immunization can be presumed and the adolescent booster dose of Tdap administered as indicated. (See <a class="local">'United States'</a> above.)</p><p class="headingAnchor" id="H2741279751"><span class="h2">Natural diphtheria or tetanus infection</span><span class="headingEndMark"> — </span>Natural infection with diphtheria or tetanus disease does not induce immunity. Individuals with diphtheria or tetanus disease should receive Td during their convalescence. (See  <a class="medical medical_review" href="/z/d/html/8047.html" rel="external">"Clinical manifestations, diagnosis, and treatment of diphtheria", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">"Tetanus", section on 'Active immunization'</a>.)</p><p class="headingAnchor" id="H586821465"><span class="h2">Natural pertussis infection</span><span class="headingEndMark"> — </span>Well-documented pertussis disease (eg, positive culture, positive polymerase chain reaction, or epidemiologic linkage to a culture-proven case) confers short-term immunity [<a href="#rid1">1</a>]. However, the duration of protection is unknown. Adolescents with a history of pertussis infection should receive Tdap according to the routine schedule [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2333413910"><span class="h2">Vaccine mix-up or unnecessary dose</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children age 7 through 10 years</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>DTaP instead of Tdap in catch-up schedule</strong> – Inadvertent administration of DTaP instead of Tdap as part of a catch-up series in a child age 7 through 9 years counts as the Tdap dose of the catch-up series. The child should receive the adolescent Tdap at age 11 through 12 years [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2">If the inadvertent administration of DTaP instead of Tdap as part of the catch-up series occurred in a child age ≥10 years, the DTaP counts as the adolescent Tdap dose (as well as the catch-up dose) [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unnecessary Tdap</strong> – Inadvertent administration of Tdap to a child age 7 through 9 years who was fully immunized with DTaP  (<a class="graphic graphic_table graphicRef117916" href="/z/d/graphic/117916.html" rel="external">table 2</a>) does not count as the adolescent Tdap [<a href="#rid7">7</a>]. The child should receive the adolescent Tdap at age 11 through 12 years.</p><p></p><p class="bulletIndent2">If the unnecessary dose of Tdap is administered to a child age ≥10 years, it counts as the adolescent Tdap dose [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unnecessary DTaP</strong> – Inadvertent administration of <a class="drug drug_pediatric" data-topicid="12763" href="/z/d/drug information/12763.html" rel="external">DTaP vaccine</a> to a child age 7 through 9 years who was fully immunized with DTaP  (<a class="graphic graphic_table graphicRef117916" href="/z/d/graphic/117916.html" rel="external">table 2</a>) does not count as the adolescent Tdap [<a href="#rid1">1</a>]. The child should receive the adolescent Tdap at age 11 through 12 years [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent2">If the unnecessary dose of DTaP is administered to a child age ≥10 years, it counts as the adolescent Tdap dose [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children ≥11 years</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>DTaP instead of Td or Tdap</strong> – Inadvertent administration of <a class="drug drug_pediatric" data-topicid="12763" href="/z/d/drug information/12763.html" rel="external">DTaP vaccine</a> (rather than Td or Tdap) to a child 11 through 18 years of age counts as the Tdap dose. The child should receive either Td or Tdap 10 years after the inadvertent dose.</p><p></p><p>Vaccine administration errors should be reported to the Vaccine Adverse Event Reporting System (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=2838" target="_blank">VAERS</a>).</p><p class="headingAnchor" id="H827721725"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Immunization during pregnancy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy"</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>Resources related to immunization in children 7 through 18 years of age include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLMlA2kPbc%2FqiOcC%2F32sLF4g1y%2BAHPIpB3%2FyasJ9MUj3%2F&amp;TOPIC_ID=2838" target="_blank">The Centers for Disease Control and Prevention</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpatient-care%2Fimmunizations%2F&amp;token=IQxLzDq4doJGUgaZgeIY01qsm8D6OPt1e2CZs7qNDD9Vki1c5XPFvhIarxbXlaH%2FgCiVnpr391CqcLRvxCctPg%3D%3D&amp;TOPIC_ID=2838" target="_blank">The American Academy of Pediatrics</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fcurrent-vis.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAH%2FK5ePuSCWLS93Qnaa3r%2F5qdQw%2FNYQGK1y%2BHqFU7TkRZLnBxvqrSwSUrCQcXZVSA%3D%3D&amp;TOPIC_ID=2838" target="_blank">Vaccine information statement</a> for Td and Tdap</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunize.org%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLoejSdbdtDpI4EQKn%2BtqVzWf7RcpJipfWejk%2Bgy%2BCZPR%2F&amp;TOPIC_ID=2838" target="_blank">Immunize.org</a></p><p></p><p class="headingAnchor" id="H429331541"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109611.html" rel="external">"Society guideline links: Pertussis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111318.html" rel="external">"Society guideline links: Diphtheria, tetanus, and pertussis vaccination"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16553.html" rel="external">"Patient education: Whooping cough (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/83176.html" rel="external">"Patient education: Tetanus (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86733.html" rel="external">"Patient education: Tdap vaccine (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/15742.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1214.html" rel="external">"Patient education: Why does my child need vaccines? (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1218.html" rel="external">"Patient education: Vaccines for children age 7 to 18 years (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Routine immunization against diphtheria, tetanus, and pertussis during childhood and adolescence provides protection against these diseases into adulthood, prevents neonatal tetanus, and prevents transmission of pertussis to young infants, who have the greatest risk of mortality. (See <a class="local">'Efficacy and effectiveness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We agree with the World Health Organization (WHO) recommendation for a booster dose of diphtheria toxoid and tetanus toxoid-containing vaccine for all adolescents. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional indications for diphtheria toxoid and tetanus toxoid-containing vaccines for children ≥7 years include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Wound management  (<a class="graphic graphic_table graphicRef61087" href="/z/d/graphic/61087.html" rel="external">table 3</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Tetanus or diphtheria disease (even if fully immunized)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Unimmunized or incompletely immunized close contact of an individual with diphtheria or pertussis disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recommendations for an adolescent booster dose of acellular pertussis vaccine vary geographically. Recommendations and schedules for individual countries are available through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fimmunizationdata.who.int%2Flisting.html%3Ftopic%3Dvaccine-schedule%26location%3D&amp;token=c1aMGh80n5JfqNiS4zUVhkGZJHzJhW7hYZJMwrVG0LFEFjNX7MxA62uBiY6p7F6hXgl8VfAnRnqUWG6LumPYIJJ9nBP597SAHqgFR7nC42s%3D&amp;TOPIC_ID=2838" target="_blank">WHO</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaccine-schedule.ecdc.europa.eu%2F&amp;token=hAC5nrgJRAh83rPs4U2YNoCvbRcaKCDdFzcO5xBYnRCBx4Y4AiuicnfZL3B%2BmfLV&amp;TOPIC_ID=2838" target="_blank">European Centre for Disease Prevention and Control</a>. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, Tdap 0.5 mL intramuscularly (IM) is routinely recommended at age 11 through 12 years of age. Thereafter, individuals should receive a booster dose of either Td 0.5 mL IM or Tdap 0.5 mL IM every 10 years. (See <a class="local">'Age 11 through 12 years'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional target groups for Tdap in the United States include (see <a class="local">'Indications'</a> above and <a class="local">'United States'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tdap-naïve adolescents age ≥13 years (catch-up immunization)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnant adolescents (a single dose during <strong>each</strong> pregnancy) (see  <a class="medical medical_review" href="/z/d/html/442.html" rel="external">"Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unvaccinated or incompletely vaccinated children age 7 through 18 years, particularly if they anticipate close contact with an infant &lt;12 months of age or are at increased risk of pertussis infection or complications of pertussis disease; Tdap should be used for at least one dose of the catch-up series (preferably the first dose)  (<a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absolute contraindications, precautions, and conditions that are incorrectly perceived as contraindications to administration of Tdap and Td are listed in the table  (<a class="graphic graphic_table graphicRef79169" href="/z/d/graphic/79169.html" rel="external">table 5</a>). (See <a class="local">'Contraindications and precautions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mild local (pain, redness, swelling) and systemic (fever, headache, fatigue) reactions are the most common adverse events after Tdap or Td. More serious reactions include syncope and Arthus-type reactions. (See <a class="local">'Adverse reactions'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018; 67:1.</a></li><li class="breakAll">American Academy of Pediatrics. Diphtheria. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.304.</li><li class="breakAll">American Academy of Pediatrics. Pertussis (whooping cough). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.578.</li><li><a class="nounderline abstract_t">Diphtheria vaccine: WHO position paper – August 2017. Wkly Epidemiol Rec 2017; 92:417.</a></li><li><a class="nounderline abstract_t">Tetanus vaccines: WHO position paper – February 2017. Wkly Epidemiol Rec 2017; 92:53.</a></li><li><a class="nounderline abstract_t">Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec 2015; 90:433.</a></li><li><a class="nounderline abstract_t">Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:77.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015. www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on June 03, 2015).</li><li class="breakAll">Centers for Disease Control and Prevention. Tetanus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015. www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on June 03, 2015).</li><li><a class="nounderline abstract_t">Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr Infect Dis J 2005; 24:S117.</a></li><li><a class="nounderline abstract_t">Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003.</a></li><li><a class="nounderline abstract_t">Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Pertussis. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015. www.cdc.gov/vaccines/pubs/pinkbook/index.html (Accessed on February 07, 2019).</li><li><a class="nounderline abstract_t">Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007; 298:2155.</a></li><li class="breakAll">Borrow R, Balmer P, Roper MH. The immunological basis for immunization series--Module 3: Tetanus update 2006. World Health Organization. Available at: http://www.who.int/immunization/documents/immunological_basis_series/en/ (Accessed on May 14, 2018).</li><li class="breakAll">Scheifele DW, Ochnio JJ. The immunological basis for immunization series--Moduel 2: Diphtheria update 2009. World Health Organization. Available at: http://www.who.int/immunization/documents/immunological_basis_series/en/ (Accessed on May 14, 2018).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Pertussis epidemic--Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:517.</a></li><li><a class="nounderline abstract_t">Witt MA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56:1248.</a></li><li><a class="nounderline abstract_t">Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131:e1716.</a></li><li><a class="nounderline abstract_t">Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454.</a></li><li><a class="nounderline abstract_t">Phadke VK, Bednarczyk RA, Salmon DA, Omer SB. Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. JAMA 2016; 315:1149.</a></li><li><a class="nounderline abstract_t">Skoff TH, Martin SW. Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis. JAMA Pediatr 2016; 170:453.</a></li><li><a class="nounderline abstract_t">Winter K, Zipprich J, Harriman K. Pertussis in California: A Tale of 2 Epidemics. Pediatr Infect Dis J 2018; 37:324.</a></li><li><a class="nounderline abstract_t">Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J 2009; 28:152.</a></li><li><a class="nounderline abstract_t">Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis 2010; 51:315.</a></li><li><a class="nounderline abstract_t">Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics 2015; 135:981.</a></li><li><a class="nounderline abstract_t">Klein NP, Bartlett J, Fireman B, Baxter R. Waning Tdap Effectiveness in Adolescents. Pediatrics 2016; 137:e20153326.</a></li><li><a class="nounderline abstract_t">Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis 2014; 210:942.</a></li><li><a class="nounderline abstract_t">Barlow RS, Reynolds LE, Cieslak PR, Sullivan AD. Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 2010-2012. Clin Infect Dis 2014; 58:1523.</a></li><li><a class="nounderline abstract_t">Cherry JD. Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease. N Engl J Med 2012; 367:785.</a></li><li><a class="nounderline abstract_t">Liko J, Robison SG, Cieslak PR. Pertussis vaccine performance in an epidemic year-Oregon, 2012. Clin Infect Dis 2014; 59:261.</a></li><li><a class="nounderline abstract_t">McNamara LA, Skoff T, Faulkner A, et al. Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012. Clin Infect Dis 2017; 65:811.</a></li><li class="breakAll">Kroger AT, Bahta L, Hunter P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Contraindications and precautions. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html (Accessed on January 19, 2022).</li><li><a class="nounderline abstract_t">Langley JM, Predy G, Guasparini R, et al. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 2007; 25:1121.</a></li><li><a class="nounderline abstract_t">Scheifele DW, Halperin SA, Ochnio JJ, et al. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 2005; 24:1059.</a></li><li><a class="nounderline abstract_t">Halperin SA, Donovan C, Marshall GS, et al. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. J Pediatric Infect Dis Soc 2019; 8:105.</a></li><li><a class="nounderline abstract_t">Kovac M, Kostanyan L, Mesaros N, et al. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study. Hum Vaccin Immunother 2018; 14:1977.</a></li><li><a class="nounderline abstract_t">Brandon D, Kimmel M, Kuriyakose SO, et al. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults. Vaccine 2018; 36:6325.</a></li><li><a class="nounderline abstract_t">Cassidy WM, Jones G, Williams K, et al. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health 2005; 36:187.</a></li><li><a class="nounderline abstract_t">Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010; 29:314.</a></li><li><a class="nounderline abstract_t">Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010; 125:1142.</a></li><li><a class="nounderline abstract_t">Kosalaraksa P, Mehlsen J, Vesikari T, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J 2015; 34:627.</a></li><li><a class="nounderline abstract_t">Schilling A, Parra MM, Gutierrez M, et al. Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines. Pediatrics 2015; 136:e563.</a></li><li><a class="nounderline abstract_t">Gasparini R, Tregnaghi M, Keshavan P, et al. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatr Infect Dis J 2016; 35:81.</a></li><li><a class="nounderline abstract_t">Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010; 29:613.</a></li><li><a class="nounderline abstract_t">Theeten H, Rümke H, Hoppener FJ, et al. Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines. Curr Med Res Opin 2007; 23:2729.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Vaccine Information Statement. Tdap vaccine. February 2015. Available at: https://www.cdc.gov/vaccines/hcp/vis/current-vis.html (Accessed on May 15, 2018).</li><li><a class="nounderline abstract_t">Braun MM, Patriarca PA, Ellenberg SS. Syncope after immunization. Arch Pediatr Adolesc Med 1997; 151:255.</a></li><li><a class="nounderline abstract_t">Woo EJ, Ball R, Braun MM. Fatal syncope-related fall after immunization. Arch Pediatr Adolesc Med 2005; 159:1083.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Syncope after vaccination--United States, January 2005-July 2007. MMWR Morb Mortal Wkly Rep 2008; 57:457.</a></li><li><a class="nounderline abstract_t">Pollard JD, Selby G. Relapsing neuropathy due to tetanus toxoid. Report of a case. J Neurol Sci 1978; 37:113.</a></li><li><a class="nounderline abstract_t">Bakshi R, Graves MC. Guillain-Barré syndrome after combined tetanus-diphtheria toxoid vaccination. J Neurol Sci 1997; 147:201.</a></li><li><a class="nounderline abstract_t">Newton N Jr, Janati A. Guillain-Barré syndrome after vaccination with purified tetanus toxoid. South Med J 1987; 80:1053.</a></li><li><a class="nounderline abstract_t">Tuttle J, Chen RT, Rantala H, et al. The risk of Guillain-Barré syndrome after tetanus-toxoid-containing vaccines in adults and children in the United States. Am J Public Health 1997; 87:2045.</a></li></ol></div><div id="topicVersionRevision">Topic 2838 Version 77.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702631" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702631" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29702631" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28776357" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diphtheria vaccine: WHO position paper–August 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28185446" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tetanus vaccines: WHO position paper–February 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320265" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pertussis vaccines: WHO position paper - September 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971933" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971933" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971933" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15931139" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acellular pertussis vaccines for adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15933223" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221778" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy of an acellular pertussis vaccine among adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16221778" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of an acellular pertussis vaccine among adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000199" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000199" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000199" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22810264" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pertussis epidemic--Washington, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23487373" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23690518" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851107" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Number and order of whole cell pertussis vaccines in infancy and disease protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26978210" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27018748" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29088031" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pertussis in California: A Tale of 2 Epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16557217" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106780" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pertussis vaccine effectiveness after mass immunization of high school students in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20578875" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25941309" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26908667" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Waning Tdap Effectiveness in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24903664" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633685" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 2010-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22894554" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748523" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pertussis vaccine performance in an epidemic year-Oregon, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017283" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017283" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reduced Severity of Pertussis in Persons With Age-Appropriate Pertussis Vaccination-United States, 2010-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17045366" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16371866" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438562" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29630439" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30197282" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15737773" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952980" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439595" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25831420" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240207" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398743" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190673" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897485" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897485" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Primary vaccination of adults with reduced antigen-content diphtheria-tetanus-acellular pertussis or dTpa-inactivated poliovirus vaccines compared to diphtheria-tetanus-toxoid vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9080932" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Syncope after immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275804" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fatal syncope-related fall after immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451756" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Syncope after vaccination--United States, January 2005-July 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/308529" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Relapsing neuropathy due to tetanus toxoid. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106128" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Guillain-Barrésyndrome after combined tetanus-diphtheria toxoid vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3616707" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Guillain-Barrésyndrome after vaccination with purified tetanus toxoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9431302" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The risk of Guillain-Barrésyndrome after tetanus-toxoid-containing vaccines in adults and children in the United States.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
